June 8, 2022
Notice to convene Annual General Meeting
Orphazyme A/SCompany announcementNo. 31/2022www.orphazyme.comCompany Registration No. 32266355 …
Pharmaceuticals, Biotechnology and Life Sciences
Orphazyme A/SCompany announcementNo. 31/2022www.orphazyme.comCompany Registration No. 32266355 …
Orphazyme A/SCompany announcementNo. 30/2022 …
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis…
Montrouge, France, June 7, 2022 DBV Technologies Announces Positive Topline Results from Phase 3 EPITOPE Trial of Viaskin Peanut in…
SOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc., (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company…
SEATTLE, June 07, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered…
Thursday, June 16th @ 10:30 a.m. ETSOUTH SAN FRANCISCO, Calif., June 07, 2022 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq:…
SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) — Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure…
Real-world, retrospective analysis of Phase 2 patients versus matched controls finds FCR001-treated patients have improved kidney function and fewer cardiometabolic…
Inventiva has been selected for inclusion in Euronext’s new segment alongside more than 100 high-growth and Tech-driven European companiesInternational investors…